Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-operative Antibiotic Prophylaxis after HoLEP
NCT05274672Phase 4Withdrawn
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Mar 2023
- Primary completion
- Feb 2025
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nitrofurantoin, cefalexin, trimethoprim + sulfamethoxazole and ciprofloxacin in urinary tract infection (UTI), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Urinary tract infection rate at 30 days. Planned start Mar 2023; status: withdrawn.
02
Drugs
nitrofurantoincefalexintrimethoprim + sulfamethoxazoleciprofloxacin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT05274672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274672.